00-0000000 false 0001805890 0001805890 2024-06-04 2024-06-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 4, 2024

 

 

Fusion Pharmaceuticals Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Canada   001-39344   Not applicable
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

270 Longwood Rd., S.  
Hamilton, Ontario, Canada   L8P 0A6
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (289) 799-0891

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common shares, no par value per share   FUSN   The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 


INTRODUCTORY NOTE

On June 4, 2024, Fusion Pharmaceuticals Inc. (“Fusion”), a corporation formed under the Canada Business Corporations Act (the “CBCA”), announced the closing of its previously announced transaction with AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden (“Parent”) and 15863210 Canada Inc., a corporation formed under the CBCA (“Purchaser”), pursuant to the arrangement agreement dated March 18, 2024 (the “Arrangement Agreement”), by and among Fusion, Parent and Purchaser. Pursuant to the terms of the Arrangement Agreement, among other things, Purchaser acquired each issued and outstanding common share (the “Shares”) of Fusion on June 4, 2024 in exchange for (i) US$21.00 in cash per Share (the “Cash Consideration”) plus (ii) one contingent value right (each, a “CVR”) per Share representing the contingent right to receive a cash payment equal to US$3.00 per Share (the “Milestone Payment”) pursuant and subject to the Arrangement Agreement and the Contingent Value Rights Agreement (the “CVR Agreement”) entered into prior to the Effective Time (as defined below) by and among Parent, Purchaser and Rights Agent (as defined therein) ((i) and (ii) collectively, the “Consideration”), by way of a plan of arrangement under section 192 of the CBCA (the “Arrangement”).

Item 2.01. Completion of Acquisition or Disposition of Assets.

In connection with the Arrangement, effective at 12:01 a.m. (Toronto Time) (the “Effective Time”) on June 4, 2024 (the “Closing Date”), Purchaser acquired all of the issued and outstanding Shares of Fusion and Fusion became a wholly-owned indirect subsidiary of Parent.

Immediately following the Effective Time, a number of steps of the Arrangement occurred, including the following:

 

   

each warrant to purchase or acquire Shares issued by Fusion (a “Warrant”) outstanding immediately prior to the Effective Time, was deemed to be assigned and transferred by the holder thereof to Fusion and thereafter cancelled in consideration for (A) a cash payment by or on behalf of Fusion equal to the number of Shares into which such Warrant was then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeded the exercise price per Share of such Warrant, and (B) one CVR with respect to each Share into which such Warrant was then exercisable, in each case subject to applicable tax withholdings and other source deductions;

 

   

each option to purchase Shares (an “Option”) with an exercise price per Share that was less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was deemed to be assigned, transferred and surrendered by the holder thereof to Fusion and thereafter cancelled in consideration for (A) a cash payment by or on behalf of Fusion equal to the number of Shares into which such Option was then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeded the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option was then exercisable, in each case subject to applicable tax withholdings and other source deductions;

 

   

each Option with an exercise price per Share that was greater than or equal to the Cash Consideration and less than the Cash Consideration plus the Milestone Payment (an “Underwater Option”) outstanding immediately prior to the Effective Time, whether vested or unvested, was deemed to be surrendered by the holder thereof to Fusion and thereafter cancelled in consideration for one CVR with respect to each Share then subject to such Underwater Option, in each case subject to applicable tax withholdings and other source deductions; provided that, each CVR issued to a holder in respect of an Underwater Option only entitles such holder to an amount in cash equal to the amount by which the Cash Consideration plus the Milestone Payment exceeds the exercise price per Share of such Underwater Option, if payable and as otherwise determined in accordance with the CVR Agreement;

 

   

each Option with an exercise price per Share that was greater than or equal to the Cash Consideration plus the Milestone Payment was deemed to be cancelled at the Effective Time without any consideration payable therefor;

 

   

each restricted stock unit issued by Fusion (a “Restricted Stock Unit”) held by a Canadian Incentive Holder (as defined in the Arrangement Agreement) and outstanding immediately prior to the Effective Time, whether vested or unvested, was deemed to be assigned, transferred and surrendered by the holder thereof to Fusion and thereafter cancelled in consideration for one Share for each Share underlying such


 

Restricted Stock Unit, subject to applicable tax withholdings and other source deductions, and each such Share was deemed to be subject to the same treatment as other Shares outstanding immediately prior to the Effective Time as described above; and

 

   

each Restricted Stock Unit held by a Non-Canadian Incentive Holder (as defined in the Arrangement Agreement) and outstanding immediately prior to the Effective Time, whether vested or unvested, was deemed to be surrendered by the holder thereof to Fusion and thereafter cancelled in consideration for (A) a cash payment by or on behalf of Fusion equal to the number of Shares underlying such Restricted Stock Unit multiplied by the Cash Consideration and (B) one CVR in respect of each Share underlying such Restricted Stock Unit, in each case subject to applicable tax withholdings and other source deductions.

The aggregate consideration payable by Purchaser to acquire the Shares, Warrants, Options, and Restricted Stock Units outstanding immediately prior to the Effective Time (other than Shares held by Purchaser and its affiliates) was approximately US$2.4 billion. There were no Options outstanding immediately prior to the Effective Time with an exercise price per Share greater than or equal to the Cash Consideration.

The foregoing description of the Arrangement Agreement and the Arrangement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Arrangement Agreement, a copy of which is attached as Exhibit 2.1 to Fusion’s Current Report on Form 8-K filed with the United States Securities and Exchange Commission (the “SEC”) on March 19, 2024, the terms of which are incorporated herein by reference.

The information contained in the Introductory Note and in Item 5.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01.

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Fusion notified the Nasdaq Stock Market (“NASDAQ”) that, as of the Effective Time, each Share issued and outstanding immediately prior to such time would be acquired by Purchaser. On June 4, 2024, in connection with the completion of the Arrangement, Fusion requested NASDAQ promptly file with the SEC a Notification of Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), on Form 25 to delist the Shares. Upon effectiveness of such Form 25, Fusion intends to file with the SEC a certification on Form 15 under the Exchange Act, requesting that the Shares be deregistered and that Fusion’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended.

Item 3.03. Material Modification to Rights of Security Holders.

On June 4, 2024, in connection with the completion of the Arrangement, each Share that was issued and outstanding immediately prior to the Effective Time was transferred to the Purchaser in exchange for the right to receive the Consideration.

The information contained in the Introductory Note and Items 2.01 and 3.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

Item 5.01. Changes in Control of Registrant

In connection with the Arrangement, a change of control of Fusion occurred and Fusion became a wholly-owned indirect subsidiary of Parent.

The information contained in the Introductory Note and Items 2.01, 3.03 and 5.02 of this Current Report on Form 8-K is incorporated by reference into this Item 5.01.


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 4, 2024, in connection with the completion of the Arrangement and following the Effective Time, John Crowley (Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer) and Mohit Rawat (President and Chief Business Officer) ceased to serve in their capacities as executive officers of Fusion.

Also, effective as of the Effective Time, each then-member of the board of directors of Fusion, consisting of Barbara Duncan, John F. Valliant, Jeremy Bender, Donald Bergstrom, Teresa Bitetti, Pablo Cagnoni, Steve Gannon, Philina Lee, and David Meek resigned from the Fusion board of directors and all committees thereof. Effective immediately following these resignations, Denise Lacombe, David E. White, and Kevin Durning became the directors of Fusion.

Item 8.01. Other Events.

Incorporated by reference is Exhibit 99.1 attached hereto, a press release issued by Fusion on June 4, 2024 announcing the completion of the Arrangement.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

 

Exhibit
Number
  

Description

2.1    Arrangement Agreement dated as of June 4, 2024, among Fusion Pharmaceuticals Inc., AstraZeneca AB, and 15863210 Canada Inc. (incorporated by reference to Exhibit 2.1 to Fusion’s Form 8-K filed on March 19, 2024)
99.1    Press release issued by Fusion Pharmaceuticals Inc. on June 4, 2024
104    Cover Page Interactive Data File (formatted as inline XBRL)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

Fusion Pharmaceuticals Inc.

Date: June 4, 2024

   

By:

 

/s/ John F. Valliant

     

John F. Valliant

     

Chief Executive Officer

Exhibit 99.1

 

LOGO

Acquisition of Fusion Pharmaceuticals Completed

HAMILTON, ON and BOSTON, June 4, 2024 /PRNewswire/ — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs), announced the successful completion of the acquisition of all of the issued and outstanding shares of Fusion by a wholly-owned subsidiary of AstraZeneca AB by way of a statutory plan of arrangement under section 192 of the Canada Business Corporations Act, referred to as the Arrangement. The Arrangement marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

The Arrangement complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced program, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. The Arrangement is also expected to strengthen AstraZeneca’s presence in and commitment to Canada.

As a result of the Arrangement, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations continuing in Canada and the US. Fusion shares will be delisted from the Nasdaq Stock Market and deregistered under the U.S. Securities Exchange Act of 1934. Fusion has submitted an application to cease to be a reporting issuer under applicable Canadian securities laws and to otherwise terminate Fusion’s Canadian public reporting requirements.

Financial Considerations

Under the terms of the definitive agreement, AstraZeneca, through a subsidiary, has acquired all of Fusion’s outstanding shares pursuant to the Arrangement for a price of $21.00 per share in cash at closing plus a non-transferable contingent value right of $3.00 per share in cash payable upon the achievement of a specified regulatory milestone prior to August 31, 2029. Combined, the upfront payment and maximum potential contingent value payment, if achieved, represent a transaction value of approximately $2.4 billion. As part of the Arrangement, AstraZeneca acquired the cash, cash equivalents and short-term investments on Fusion’s balance sheet, which totaled $211 million as of March 31, 2024.

The upfront consideration has been provided to Equiniti Trust Company, LLC, as depositary under the Arrangement, and, along with the contingent value rights, will be delivered to former securityholders (as applicable) of Fusion as soon as practicable on or after the date hereof.


About Fusion

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation RCs. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion’s clinical-stage development portfolio includes lead program, FPI-2265, targeting PSMA for mCRPC and novel RCs targeting solid tumors. Fusion has a fully operational Good Manufacturing Practice compliant state-of-the-art radiopharmaceutical manufacturing facility to meet supply demand for Fusion’s growing pipeline of radioconjugates.

Forward Looking Information

To the extent any statements made in this communication contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and forward-looking information under Canadian securities law (collectively, “forward-looking statements”). Certain statements in this communication may constitute forward-looking statements, which reflect the expectations of Fusion’s management. The use of words such as “may,” “will,” “could,” “should,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “seeks,” “endeavor,” “potential,” “continue” or the negative of such words or other similar expressions can be used to identify forward-looking statements.

Fusion’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors including but not limited to risks related to the ability of Fusion to meet the regulatory milestone, the response of business partners and competitors to the completion of the Arrangement, and/or potential difficulties in employee retention as a result of the Arrangement; and the failure to realize the expected benefits of the


Arrangement. Please also refer to the factors discussed under “Risk Factors” and “Special Note Regarding Forward-looking Information” in Fusion’s Annual Report on Form 10-K for the year ended December 31, 2023, with the U.S. Securities Exchange Commission (“SEC”), each as updated by Fusion’s continuous disclosure filings, and the factors discussed under “Risk Factors” in the Management Information Circular and Proxy Statement dated April 25, 2024, all of which are available at www.sedarplus.ca.

Forward-looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not or the times at or by which such performance or results will be achieved. All forward-looking statements herein are qualified in their entirety by its cautionary statement and are made as of the date of this document. Fusion disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Notes

Radioconjugates in oncology

RCs combine the precise targeting of antibodies, small molecules or peptides with potent medical radioisotopes to deliver radiation directly to cancer cells. By seeking out cancer cells, RCs provide a more precise mechanism of cancer cell killing compared with traditional radiation therapy, with the goal of improving efficacy while minimizing toxicity on healthy cells. RCs are administered via systemic delivery, which enables their use in tumour types not accessible to external beam radiation and the targeting of cancer cells that have spread from the main tumour to other sites in the body.

About FPI-2265

FPI-2265 is an actinium-225 based PSMA-targeting RC for mCRPC, currently in a Phase II trial.

Actinium-225 emits alpha particles and holds the promise of being a next-generation radioisotope in cancer treatment. By delivering a greater radiation dose over a shorter distance, alpha particles such as actinium-225 have the potential for more potent cancer cell killing, and targeted delivery, thereby minimizing damage to surrounding healthy tissue.

For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com

v3.24.1.1.u2
Document and Entity Information
Jun. 04, 2024
Cover [Abstract]  
Entity Tax Identification Number 00-0000000
Amendment Flag false
Entity Central Index Key 0001805890
Document Type 8-K
Document Period End Date Jun. 04, 2024
Entity Registrant Name Fusion Pharmaceuticals Inc.
Entity Incorporation State Country Code Z4
Entity File Number 001-39344
Entity Address, Address Line One 270 Longwood Rd., S.
Entity Address, City or Town Hamilton
Entity Address, State or Province ON
Entity Address, Country CA
Entity Address, Postal Zip Code L8P 0A6
City Area Code (289)
Local Phone Number 799-0891
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common shares, no par value per share
Trading Symbol FUSN
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false

Fusion Pharmaceuticals (NASDAQ:FUSN)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024 Fusion Pharmaceuticals 차트를 더 보려면 여기를 클릭.
Fusion Pharmaceuticals (NASDAQ:FUSN)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024 Fusion Pharmaceuticals 차트를 더 보려면 여기를 클릭.